Co-founded by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS), the Transplant Therapeutics Consortium (TTC) has the goal of identifying mechanisms and drug development tools to accelerate drug discovery for transplant patients, through the collaborative involvement of key stakeholders in the field. The consortium is first focusing on kidney transplant but may expand to other solid organ transplants in the future.
Through the TTC, members are able to share expertise, resources, and data in a neutral, precompetitive, and confidential environment. The initial scope of the TIC will include three areas of focus:
- Developing quantitative Drug Development Tools (DDTs) from patient control data
- Evaluating the current composite endpoint for kidney transplant and assessing if a weighted composite endpoint could be applied for better clinical outcomes
- Exploring methodologies that are capable of effectively incorporating the voice of the patient into kidney transplant clinical trial design